MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Neurocrine Biosciences Cash Conversion Cycle 2011-2026 | NBIX
Annual Cash Conversion Cycle Neurocrine Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 517 | 585 | 414 | 582 | 802 | 868 | -1.36 K | -174 | -1.57 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 868 | -1.57 K | 73 |
Quarterly Cash Conversion Cycle Neurocrine Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 542 | 657 | - | 573 | 466 | 538 | - | 320 | 337 | 448 | - | 312 | 307 | 656 | - | 634 | 908 | 973 | 57.8 | 1 K | 1.11 K | 1.04 K | 47.3 | 770 | 1.05 K | 641 | 39.8 | 673 | 1.21 K | 356 | 30.1 | 168 | -93.2 | - | - | - | - | 45.9 | - | - | - | 69.3 | - | - | - | - | 175 | 7.07 | 173 | 1.05 K | 58.6 | 137 | 122 | 64.8 | 15.6 | 4.17 | 14.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.21 K | -93.2 | 422 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.91 | 3.25 % | $ 6.69 M | China |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.6 | -4.75 % | $ 243 M |  Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.51 | -0.73 % | $ 3.73 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.07 | -0.61 % | $ 435 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 22.51 | -3.35 % | $ 2.86 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.41 | -4.73 % | $ 375 M | Britain |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
11.9 | - | - | $ 35.4 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-32.5 K | $ 1.05 | -1.42 % | $ 12.8 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |